Haemophilia: Medical Treatments

(asked on 11th October 2018) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, with reference to commissioning criteria 6a of NHS England’s Criteria for the Prescribing of Enhanced Half-Life Blood Factors, published on 22 September 2016, for what reason the prescribed factor VIII dose per infusion should be the same as the previous treatment regimen; and whether a patient who achieved higher trough levels than before from a higher dosage of EHLs than on their previous regimen would be switched back to their previous treatment regimen.


Answered by
Steve Brine Portrait
Steve Brine
This question was answered on 16th October 2018

The Criteria for the Prescribing of Enhanced Half-Life (EHL) Blood Factors were published after clinical consultation and advice. Clinical advice was consistent on all criteria. The advice received was that this would be clinically effective and appropriate to deliver the claimed benefits of treatment with an EHL factor compared with a standard half-life factor. The requirement to switch back to a standard half-life FVIII product is stipulated irrespective of any trough level achieved with an EHL factor VIII. The target trough level remains at 1%, although sometimes lower trough levels are appropriate as per British Society for Haematology guidelines.

Reticulating Splines